Regen BioPharma (Regen BioPharma) Change In Payables And Accrued Expense : $0.02 Mil (TTM As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Regen BioPharma Change In Payables And Accrued Expense?

Regen BioPharma's Change In Payables And Accrued Expense for the quarter that ended in Mar. 2024 was $-0.03 Mil. It means Regen BioPharma's Accounts Payable & Accrued Expense declined by $0.03 Mil from Dec. 2023 to Mar. 2024 .

Regen BioPharma's Change In Payables And Accrued Expense for the fiscal year that ended in Sep. 2023 was $0.06 Mil. It means Regen BioPharma's Accounts Payable & Accrued Expense increased by $0.06 Mil from Sep. 2022 to Sep. 2023 .

Regen BioPharma Change In Payables And Accrued Expense Historical Data

The historical data trend for Regen BioPharma's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regen BioPharma Change In Payables And Accrued Expense Chart

Regen BioPharma Annual Data

Trend

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Change In Payables And Accrued Expense

Get a 7-Day Free Trial

0.62

0.59

0.35

0.05

0.06

Regen BioPharma Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Payables And Accrued Expense	Get a 7-Day Free Trial															0.02	0.01	0.02	0.03	-0.03

Regen BioPharma Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.02 Mil.

Regen BioPharma Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of Regen BioPharma's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Regen BioPharma (Regen BioPharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regen BioPharma Inc (OTCPK:RGBP) » Definitions » Change In Payables And Accrued Expense

Comparable Companies

Traded in Other Exchanges

RGBPP.PFD:USA

Address

4700 Spring Street, Suite 304, La Mesa, CA, USA, 91942

Website

https://www.regenbiopharmainc.com

Regen BioPharma Inc is a US-based biotechnology company. It focuses on the development of regenerative medical applications in the stem cell space. The company's principal products and services include HemaXellarate I, HemaXellerate II, dCell Vax, NR2F6, Tcellvax, identification of Small Molecules, and others. HemaXellarate I and HemaXellerate II is a cellular therapy designed to heal damaged bone marrow. dCell Vax is a therapy whereby dendritic cells of the cancer patient are harvested from the body. Tcellvax is an autologous cellular product comprised of NR2F6 gene-silenced peripheral blood mononuclear cells.